Optimizing Immunosuppression After Kidney Transplant
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial is testing whether a blood test called Prospera can help doctors safely lower the amount of anti-rejection medicines you take after a kidney transplant. It is for people who recently received a kidney and are on standard anti-rejection drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received a kidney transplant in the last 3 months.
- You are on a maintenance regimen with tacrolimus and either mycophenolate sodium or mycophenolate mofetil, with or without steroids.
- You are 18 years or older and able to give informed consent.
- You have not had any other organ or tissue transplants.
- You are not currently on dialysis and do not have a serious medical condition like cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This study is for people whose first kidney transplant has stopped working and who need to start dialysis. The goal is to see if continuing certain anti-rejection medications can help prevent the body from making antibodies that would make it harder to get another transplant in the future.
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
This trial is testing a stronger combination of four immune-suppressing medicines (including mTOR inhibitors) to help prevent rejection in kidney transplant patients who have a high level of antibodies. It aims to see if this approach works better than standard care for these 'sensitized' patients.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.